Strengthening Supply Chains: The EU Critical Medicines Act
The European Medicines Agency (EMA) has welcomed the provisional political agreement on the EU Critical Medicines Act, an initiative designed to enhance the availability, production, and supply of critical medicines throughout the European Union. This agreement represents a key advancement in addressing vulnerabilities exposed by recent global disruptions, including the COVID-19 pandemic and geopolitical tensions, which have contributed to medicine shortages arising from manufacturing issues, supply chain weaknesses, and competition for resources. By integrating regulatory measures with industrial policy tools, the EU Critical Medicines Act aims to build more secure and sustainable supply chains while supporting access to medicines of common interest, such as those for rare diseases, that may face availability disparities across Member States.
Legislative Push for Supply Security
The agreement introduces targeted provisions that prioritize diversification of supply sources and incentives for European manufacturing capacity, particularly through Strategic Projects that facilitate funding access, streamlined permitting, and administrative support for critical medicines and their active substances. Public procurement procedures will require criteria beyond price, such as monitoring of supply chains and, in cases of high dependency on limited third-country suppliers, preferences for EU-based production to reduce structural risks. Additionally, mechanisms for collaborative procurement and coordinated contingency stock management across Member States seek to prevent negative spillover effects on availability in other regions, while strategic international partnerships are encouraged to broaden sourcing options. These elements build directly on the Union List of Critical Medicines, encompassing over 200 active substances assessed as essential for healthcare continuity, and leverage the Medicines Shortages Steering Group (MSSG) for ongoing supply chain vulnerability evaluations that inform policy decisions under both the EU Critical Medicines Act and the revised EU pharmaceutical legislation.
Foundations in Shortage Response History
The EU Critical Medicines Act emerges from a sequence of EU initiatives responding to persistent medicine shortages documented over the past decade, with the European Commission proposing the Act in 2025 as part of efforts to complete the European Health Union and complement the modernization of pharmaceutical legislation agreed in December. Methodological foundations include systematic assessments by the MSSG of supply chain vulnerabilities for medicines on the Union List, drawing on data from industry notifications, shortage monitoring platforms, and stakeholder consultations such as those conducted by the Critical Medicines Alliance. This framework extends EMA’s expanded mandate for shortage management and incorporates tools like the European Shortages Monitoring Platform to enable data-driven exchanges between regulators and manufacturers, ensuring that evaluations of manufacturing capacity, input material dependencies, and market access barriers remain evidence-based and regularly updated.
Impacts on Costs and Patient Access
The EU Critical Medicines Act’s emphasis on industrial policy interventions, including state aid facilitation and joint procurement frameworks, carries significant implications for health economics and outcomes research by potentially altering cost structures, pricing negotiations, and reimbursement pathways for critical medicines across EU markets. Measures favoring diversified and EU-centric supply chains may influence market access strategies, as manufacturers adapt to procurement requirements that value supply reliability alongside therapeutic value, thereby affecting health technology assessment considerations and budget impact analyses in national systems. For outcomes research, the Act’s focus on reducing shortages supports more consistent patient access data, which could enhance real-world evidence generation on treatment continuity and healthcare system efficiencies, while collaborative procurement options offer opportunities to address disparities in availability for orphan medicines and other products of common interest. Overall, these developments align with broader trends toward resilient pharmaceutical ecosystems, positioning the EU Critical Medicines Act to work alongside regulatory reforms in promoting sustainable investment and equitable resource allocation within the EU.
